Using the 25% percentile of IHC-scores to define positive status for ERβ1, total ERβ and ERβ2/cx, we observed that 58% of ERα-negative tumours were positive for ERβ1 (n=122/210), 60% positive for total ERβ (n=115/192) and 57% of cancers were positive for ERβ2/cx (n=114/199; Table 2). Here, ESR2 is linked to neoplasm.